BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37029785)

  • 1. The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib.
    Sánchez-Fdez A; Matilla-Almazán S; Montero JC; Del Carmen S; Abad M; García-Alonso S; Bhattacharya S; Calar K; de la Puente P; Ocaña A; Pandiella A; Esparís-Ogando A
    Clin Transl Med; 2023 Apr; 13(4):e1217. PubMed ID: 37029785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual inhibition of MEK1/2 and MEK5 suppresses the EMT/migration axis in triple-negative breast cancer through FRA-1 regulation.
    Hoang VT; Matossian MD; La J; Hoang K; Ucar DA; Elliott S; Burks HE; Wright TD; Patel S; Bhatt A; Phamduy T; Chrisey D; Buechlein A; Rusch DB; Nephew KP; Anbalagan M; Rowan B; Cavanaugh JE; Flaherty PT; Miele L; Collins-Burow BM; Burow ME
    J Cell Biochem; 2021 Aug; 122(8):835-850. PubMed ID: 33876843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
    Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
    Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer.
    Cristea S; Coles GL; Hornburg D; Gershkovitz M; Arand J; Cao S; Sen T; Williamson SC; Kim JW; Drainas AP; He A; Cam LL; Byers LA; Snyder MP; Contrepois K; Sage J
    Cancer Res; 2020 Mar; 80(6):1293-1303. PubMed ID: 31969375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WNK1 activates ERK5 by an MEKK2/3-dependent mechanism.
    Xu BE; Stippec S; Lenertz L; Lee BH; Zhang W; Lee YK; Cobb MH
    J Biol Chem; 2004 Feb; 279(9):7826-31. PubMed ID: 14681216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications.
    Sánchez-Fdez A; Matilla-Almazán S; Del Carmen S; Abad M; Arconada-Luque E; Jiménez-Suárez J; Chinchilla-Tábora LM; Ruíz-Hidalgo MJ; Sánchez-Prieto R; Pandiella A; Esparís-Ogando A
    Exp Mol Med; 2023 Jun; 55(6):1247-1257. PubMed ID: 37332046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer.
    Sánchez-Fdez A; Re-Louhau MF; Rodríguez-Núñez P; Ludeña D; Matilla-Almazán S; Pandiella A; Esparís-Ogando A
    NPJ Precis Oncol; 2021 Aug; 5(1):78. PubMed ID: 34404896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MEK5/ERK5 signalling pathway in cancer: a promising novel therapeutic target.
    Simões AE; Rodrigues CM; Borralho PM
    Drug Discov Today; 2016 Oct; 21(10):1654-1663. PubMed ID: 27320690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival.
    Diéguez-Martínez N; Espinosa-Gil S; Yoldi G; Megías-Roda E; Bolinaga-Ayala I; Viñas-Casas M; Gorgisen G; Domingo-Ortí I; Pérez-Montoyo H; Bayascas JR; Colas E; Dolcet X; Lizcano JM
    Cell Mol Life Sci; 2022 Sep; 79(10):524. PubMed ID: 36123565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
    Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
    Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
    Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
    J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation.
    Simões AE; Pereira DM; Gomes SE; Brito H; Carvalho T; French A; Castro RE; Steer CJ; Thibodeau SN; Rodrigues CM; Borralho PM
    Cell Death Dis; 2015 Apr; 6(4):e1718. PubMed ID: 25855966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The CREB1/WNK1 axis promotes the tumorigenesis of ovarian cancer via regulating HIF-1.
    Ma Y; Zong H; Pan P; Shang H; Yang X
    Exp Cell Res; 2024 May; 438(1):114006. PubMed ID: 38599542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PB1 domain-dependent signaling complex is required for extracellular signal-regulated kinase 5 activation.
    Nakamura K; Uhlik MT; Johnson NL; Hahn KM; Johnson GL
    Mol Cell Biol; 2006 Mar; 26(6):2065-79. PubMed ID: 16507987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the MEK5-ERK5 module in human neutrophils and its relationship to ERK1/ERK2 in the chemotactic response.
    Hii CS; Anson DS; Costabile M; Mukaro V; Dunning K; Ferrante A
    J Biol Chem; 2004 Nov; 279(48):49825-34. PubMed ID: 15381709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype.
    Zhou C; Nitschke AM; Xiong W; Zhang Q; Tang Y; Bloch M; Elliott S; Zhu Y; Bazzone L; Yu D; Weldon CB; Schiff R; McLachlan JA; Beckman BS; Wiese TE; Nephew KP; Shan B; Burow ME; Wang G
    Breast Cancer Res; 2008; 10(6):R105. PubMed ID: 19087274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of either ERK1/2 or ERK5 MAP kinase pathways can lead to disruption of the actin cytoskeleton.
    Barros JC; Marshall CJ
    J Cell Sci; 2005 Apr; 118(Pt 8):1663-71. PubMed ID: 15797923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-redundant function of the MEK5-ERK5 pathway in thymocyte apoptosis.
    Sohn SJ; Lewis GM; Winoto A
    EMBO J; 2008 Jul; 27(13):1896-906. PubMed ID: 18548009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
    Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY
    Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK5 and ERK5 are localized in the nuclei of resting as well as stimulated cells, while MEKK2 translocates from the cytosol to the nucleus upon stimulation.
    Raviv Z; Kalie E; Seger R
    J Cell Sci; 2004 Apr; 117(Pt 9):1773-84. PubMed ID: 15075238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.